| Literature DB >> 3865774 |
J J Kavanagh, K Y Yeung, N Savaraj, I H Krakoff.
Abstract
Thirteen patients were treated with both the oral and intravenous preparations of 4-demethoxydaunorubicin (DMDR). The drug was well tolerated in both forms. Neutropenia was the dose-limiting side-effect. Approximately 30% of the compound was absorbed when given orally. The maximum tolerated dose was 12.5 mg/m2 intravenously or 50 mg/m2 (10 mg/m2 q d X 5) orally, given every 21-28 days.Entities:
Mesh：
Substances：
Year: 1985 PMID： 3865774 DOI： 10.1016/0277-5379(85)90013-6
Source DB: PubMed Journal: Eur J Cancer Clin Oncol ISSN： 0277-5379